RxDoctor Payments Data

Umar Sharif Khawaja

Endocrinology, Diabetes & Metabolism · Ridgewood, NJNPI 1508399163

Payments from drug & device makers

$997in general payments, 2019–2025

Across 25 payments — averaging $39.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$194
  • Abbott$168
  • Novo Nordisk$161
  • Corcept Therapeutics$161
  • Fresenius Kabi USA, LLC$125
  • Paratek Pharmaceuticals, Inc.$120
  • plus $69 from 2 others

What the payments were for

  • Food & beverage$997100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$997 in reported general payments places this provider in the 35th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

See all endocrinology, diabetes & metabolism providers in New Jersey

Medicare billing

Part B allowed, 2024
$305,990
Medicare patients
522
Services billed
4,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide140$169,393
JardianceEmpagliflozin70$84,385
JanuviaSitagliptin Phosphate43$53,156
MounjaroTirzepatide30$33,749
FarxigaDapagliflozin Propanediol25$29,378
TrulicityDulaglutide20$28,819
TradjentaLinagliptin16$20,029
Fiasp FlextouchInsulin Aspart (Niacinamide)26$13,841
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$12,107
JanumetSitagliptin Phos/Metformin Hcl12$9,013
Tresiba Flextouch U-100Insulin Degludec13$7,979
Lantus SolostarInsulin Glargine,hum.Rec.Anlog64$6,982
Humalog Kwikpen U-100Insulin Lispro32$5,710
Novolog FlexpenInsulin Aspart17$4,846
Nano 2nd Gen Pen NeedlePen Needle, Diabetic49$4,270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$161$169,393140 claims
Lilly USA, LLCMounjaro, Trulicity$32$62,56750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

Other endocrinology, diabetes & metabolism in Ridgewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →